Efficacy and Safety of Von Willebrand Factor Concentrate Almost Devoid of Factor VIII (Wilfactin) in Paediatric Patients Under 6 Years of Age with Severe Von Willebrand Disease

Overview

Journal Blood Transfus

Specialty Hematology

Date 2022 May 11

PMID 35543677

Authors

Emna Gouider

Anna Klukowska

Philip Maes

Helen Platokouki

Sonia Pujol

Celine Henriet

Francoise Bridey

Jenny Goudemand

Affiliations

Soon will be listed here.

Abstract

Background: Plasma-derived von Willebrand factor (VWF) (Wilfactin, LFB, France) was developed for prophylaxis and treatment of haemorrhages in both adults and adolescents with von Willebrand disease (VWD). Replacement therapy in paediatric patients is a key element of the clinical trial programme.

Material And Methods: Patients aged <6 years with severe VWD were enrolled in a multinational, open-label study to evaluate the in vivo recovery for Wilfactin, and its efficacy in preventing and treating bleeding episodes and during surgery. Overall haemostatic efficacy based on a 4-point scale was assessed by investigators. The treatment period ≥18 months investigated the long-term safety.

Results: Nine patients, including 7 with type 3 VWD were exposed to treatment with Wilfactin for up to 4.2 years. Recovery of VWF in 7 patients (n=5 type 3, n=1 type 2, n=1 type 1) was 1.8±0.4 IU/dL per IU/kg. Of the 62 bleeds, 89% were controlled with one (73%) or two (16%) infusions of Wilfactin. The median dose per infusion was 54 IU/kg. A factor VIII dose was co-administered in 1.6% of bleeds. "Excellent"/"Good" haemostatic efficacy was achieved in 90.3% of episodes. Six patients underwent 11 minor surgical interventions. Treatment duration was 1 day (range: 1-6 days) with a dose administered 30-60 minutes before procedure of 56 IU/kg (range: 41-106 IU/kg). Haemostasis was rated as "Excellent" in all surgeries. During 4-year prophylactic treatment in one patient, breakthrough bleeds were reported in 2.2% of infusions. No VWF inhibitors, thromboembolic events or allergic/anaphylactic-type reactions were observed following a total exposure of 770 days.

Discussion: The results show that Wilfactin provides a safe and effective treatment in patients <6 years of age with severe VWD.

References

Auerswald G, Djambas Khayat C, Stasyshyn O, Iosava G, Romashevskaya I, Lopez M . Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study). J Blood Med. 2020; 11:213-225. PMC: 7319533. DOI: 10.2147/JBM.S236789. View

Sadler J, Budde U, Eikenboom J, Favaloro E, Hill F, Holmberg L . Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4(10):2103-14. DOI: 10.1111/j.1538-7836.2006.02146.x. View

Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S . The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2010; 17(3):463-9. DOI: 10.1111/j.1365-2516.2010.02445.x. View

Riddell A, Vinayagam S, Gomez K, Laffan M, Mckinnon T . Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay. Res Pract Thromb Haemost. 2019; 3(1):126-135. PMC: 6332833. DOI: 10.1002/rth2.12166. View

Werner E . von Willebrand disease in children and adolescents. Pediatr Clin North Am. 1996; 43(3):683-707. DOI: 10.1016/s0031-3955(05)70428-4. View

de Wee E, Sanders Y, Mauser-Bunschoten E, van der Bom J, Degenaar-Dujardin M, Eikenboom J . Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012; 108(4):683-92. DOI: 10.1160/TH12-04-0244. View

Siaka C, Rugeri L, Caron C, Goudemand J . A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003; 9(3):303-8. DOI: 10.1046/j.1365-2516.2003.00750.x. View

Mannucci P . Treatment of von Willebrand's Disease. N Engl J Med. 2004; 351(7):683-94. DOI: 10.1056/NEJMra040403. View

Goudemand J, Scharrer I, Berntorp E, Lee C, Borel-Derlon A, Stieltjes N . Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005; 3(10):2219-27. DOI: 10.1111/j.1538-7836.2005.01435.x. View

10.

Berntorp E, Windyga J . Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia. 2009; 15(1):122-30. DOI: 10.1111/j.1365-2516.2008.01901.x. View

11.

Abshire T, Federici A, Alvarez M, Bowen J, Carcao M, Cox Gill J . Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2012; 19(1):76-81. PMC: 4514514. DOI: 10.1111/j.1365-2516.2012.02916.x. View

12.

Bjorkman S, Blanchette V, Fischer K, Oh M, Spotts G, Schroth P . Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010; 8(4):730-6. PMC: 2855866. DOI: 10.1111/j.1538-7836.2010.03757.x. View

13.

Khair K, Batty P, Riat R, Bowles L, Burgess C, Chen Y . Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience. Haemophilia. 2014; 21(1):e44-50. DOI: 10.1111/hae.12497. View

14.

Nowak-Gottl U, Krumpel A, Russo A, Jansen M . Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information. Haemophilia. 2013; 19(6):887-92. DOI: 10.1111/hae.12237. View

15.

Nichols W, Hultin M, James A, Manco-Johnson M, Montgomery R, Ortel T . von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008; 14(2):171-232. DOI: 10.1111/j.1365-2516.2007.01643.x. View

16.

Halimeh S, Krumpel A, Rott H, Bogdanova N, Budde U, Manner D . Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost. 2011; 105(4):597-604. DOI: 10.1160/TH10-09-0616. View

17.

Borel-Derlon A, Federici A, Roussel-Robert V, Goudemand J, Lee C, Scharrer I . Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007; 5(6):1115-24. DOI: 10.1111/j.1538-7836.2007.02562.x. View

18.

Drillaud N, Ardillon L, Ternisien C, Valentin J, Fouassier M, Gillet B . Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?. Transfus Med Rev. 2019; 34(2):128-129. DOI: 10.1016/j.tmrv.2019.10.004. View

19.

Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S . In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang. 2004; 86(2):100-4. DOI: 10.1111/j.0042-9007.2004.00398.x. View

20.

Lillicrap D, Poon M, Walker I, Xie F, Schwartz B . Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002; 87(2):224-30. View